• Latest Posts
Podcast 1 Dec 2023

Ipsen drug gives hope for liver disease patients

European Biotechs Fire up Deals to Develop Parkinson’s Treatments

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

French Ipsen closes €700M deal for Californian Cancer Drug

After Failing Phase III, Active Biotech is back to square one